Jazz Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Dublin Ireland (2003)

Organization Overview

First Clinical Trial
2003
NCT00003966
First Marketed Drug
2003
sodium oxybate (xyrem)
First NDA Approval
2019
solriamfetol (Sunosi)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Jazz | JAZZ | Jazz Pharamceuticals | Jazz Pharmaceuticals | Jazz Pharmaceuticals, Inc | Jazz Pharmaceuticals, Inc. | JAZZ PHARMACEUTICALS IRELAND LIMITED | JAZZ PHARMS | JAZZ PHARMS III | JAZZ PHARMS INC